First Trust Nasdaq Pharmaceuticals ETF Rating → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Free FTXH Stock Alerts $27.17 -0.17 (-0.62%) (As of 05/16/2024 ET) Add Compare Share Share RatingsStock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsShort InterestSocial MediaStock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsShort InterestSocial Media First Trust Nasdaq Pharmaceuticals ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.FTXH Aggregate RatingModerate Buy2.57Holdings in FTXH have an aggregate rating of Moderate Buy based on 646 analyst ratings issued in the past year covering 50 companies (99.9% of the portfolio).FTXH Aggregate Price Target$32.2918.86% UpsideHigh Prediction$40.74Average Prediction$32.29Low Prediction$24.44Holdings in FTXH have an aggregate price target of $32.29 and a range of $24.44 to $40.74 covering 50 companies (99.9% of the portfolio).FTXH Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy7 Buy rating(s)Moderate Buy32 Moderate Buy rating(s)Hold10 Hold rating(s)Reduce0 Reduce rating(s)Sell1 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by First Trust Nasdaq Pharmaceuticals ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 50 FTXH Holdings Export to ExcelWeightIn ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings7.78%PFEPfizer$28.93+0.4%5 of 5 stars2.40$35.86 23.9%157.45%MRKMerck & Co., Inc.$130.89-0.6%5 of 5 stars2.58$131.33 0.3%12Analyst Revision6.91%ABBVAbbVie$164.35+0.3%4 of 5 stars2.77$174.31 6.1%13Short Interest ↑Analyst Revision6.87%JNJJohnson & Johnson$154.27+1.0%5 of 5 stars2.46$175.86 14.0%13Analyst ForecastShort Interest ↑6.44%BMYBristol-Myers Squibb$44.11-1.0%5 of 5 stars2.11$60.00 36.0%194.22%AMGNAmgen$314.72-1.4%5 of 5 stars2.52$305.65 -2.9%21Options Volume3.91%UTHRUnited Therapeutics$272.22-0.2%5 of 5 stars2.90$308.78 13.4%10Analyst UpgradeInsider Selling3.72%BIIBBiogen$230.04-2.2%5 of 5 stars2.65$288.46 25.4%26Analyst ForecastNews Coverage3.68%REGNRegeneron Pharmaceuticals$967.98-1.0%4 of 5 stars2.76$989.36 2.2%21Analyst ForecastInsider SellingPositive News3.62%LLYEli Lilly and Company$771.12-2.0%5 of 5 stars2.84$769.53 -0.2%19Analyst ForecastShort Interest ↓3.54%VTRSViatris$11.02-0.5%1 of 5 stars1.33$11.00 -0.2%33.54%VRTXVertex Pharmaceuticals$440.64+0.7%4 of 5 stars2.48$432.18 -1.9%253.34%GILDGilead Sciences$67.86+1.3%5 of 5 stars2.35$83.69 23.3%173.28%CAHCardinal Health$98.70+1.6%5 of 5 stars2.50$107.57 9.0%12Analyst Forecast3.13%ZTSZoetis$173.72+0.3%5 of 5 stars3.00$211.75 21.9%73.02%JAZZJazz Pharmaceuticals$110.49+0.7%5 of 5 stars2.85$192.75 74.5%132.88%OGNOrganon & Co.$21.52-0.6%5 of 5 stars2.50$22.60 5.0%42.03%CRLCharles River Laboratories International$224.75-3.4%5 of 5 stars2.64$255.27 13.6%11Insider SellingHigh Trading Volume1.56%PRGOPerrigo$30.10-0.4%5 of 5 stars3.00$40.67 35.1%3Analyst UpgradeOptions Volume1.46%MEDPMedpace$393.28-3.1%5 of 5 stars2.80$443.00 12.6%5Analyst Revision1.28%HALOHalozyme Therapeutics$45.39-0.9%5 of 5 stars2.83$53.14 17.1%60.96%INCYIncyte$56.86-0.3%5 of 5 stars2.47$74.93 31.8%17Short Interest ↑0.93%ALKSAlkermes$24.46+1.3%5 of 5 stars2.50$35.38 44.6%10Positive News0.91%NBIXNeurocrine Biosciences$141.91-0.1%5 of 5 stars2.79$148.96 5.0%24Analyst ForecastInsider SellingPositive News0.89%EXELExelixis$21.23+0.5%5 of 5 stars2.59$26.13 23.1%17Analyst ForecastInsider SellingShort Interest ↑0.82%PBHPrestige Consumer Healthcare$64.98-2.2%4 of 5 stars2.50$110.00 69.3%3Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageHigh Trading Volume0.70%ELANElanco Animal Health$16.97-0.4%3 of 5 stars2.57$18.29 7.8%7Short Interest ↓0.59%BPMCBlueprint Medicines$106.64-0.1%1 of 5 stars2.53$102.65 -3.7%17Analyst ForecastShort Interest ↑Analyst Revision0.59%ILMNIllumina$114.46-0.5%5 of 5 stars2.30$164.65 43.8%20Short Interest ↓0.56%EXASExact Sciences$51.95-2.6%5 of 5 stars2.92$95.40 83.6%13Short Interest ↓0.54%SRPTSarepta Therapeutics$132.74+0.2%4 of 5 stars2.86$161.81 21.9%14Analyst UpgradePositive News0.52%KRYSKrystal Biotech$163.78+0.4%5 of 5 stars3.00$171.00 4.4%9Short Interest ↑0.52%VKTXViking Therapeutics$69.06-11.5%5 of 5 stars3.00$112.25 62.5%10Analyst ForecastGap DownHigh Trading Volume0.52%RYTMRhythm Pharmaceuticals$39.17-1.1%3 of 5 stars2.83$54.33 38.7%60.52%ROIVRoivant Sciences$11.41-0.8%2 of 5 stars2.90$16.90 48.1%10News CoveragePositive News0.52%MRUSMerus$45.02-0.4%3 of 5 stars3.00$56.33 25.1%11Analyst Upgrade0.51%ITCIIntra-Cellular Therapies$66.53-0.5%5 of 5 stars2.90$90.17 35.5%10Positive News0.50%BMRNBioMarin Pharmaceutical$76.97-4.3%5 of 5 stars2.65$107.79 40.0%20Analyst ForecastShort Interest ↑Analyst RevisionHigh Trading Volume0.50%ACLXArcellx$52.79+2.1%3 of 5 stars3.08$78.73 49.1%13Analyst Forecast0.49%IDYAIDEAYA Biosciences$41.53-2.1%3 of 5 stars3.00$46.80 12.7%12Insider SellingShort Interest ↑News Coverage0.49%TGTXTG Therapeutics$17.42-1.7%4 of 5 stars2.83$29.83 71.3%6Positive News0.49%MLTXMoonLake Immunotherapeutics$40.86+0.4%3 of 5 stars2.75$74.46 82.2%12Earnings Report0.48%IONSIonis Pharmaceuticals$37.62-4.1%5 of 5 stars2.71$59.54 58.3%14Short Interest ↓Gap DownHigh Trading Volume0.45%KYMRKymera Therapeutics$35.60-0.9%1 of 5 stars2.50$41.10 15.4%120.43%RAREUltragenyx Pharmaceutical$42.61+3.6%4 of 5 stars2.92$87.85 106.2%12Positive News0.43%NUVLNuvalent$72.64+1.3%2 of 5 stars2.90$90.78 25.0%10Insider SellingNews Coverage0.38%ACADACADIA Pharmaceuticals$14.85-1.8%4 of 5 stars2.75$28.94 94.9%16Short Interest ↑0.37%ARVNArvinas$32.11-0.7%3 of 5 stars2.88$61.13 90.4%16News CoverageGap Up0.34%CRSPCRISPR Therapeutics$55.67-2.3%3 of 5 stars2.35$73.93 32.8%17Gap Up0.30%BEAMBeam Therapeutics$23.79-1.3%2 of 5 stars2.38$40.18 68.9%13Short Interest ↑ This page (NASDAQ:FTXH) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!Gold Safe ExchangeHow Biden has already won 2024Porter & Company348 million Americans lives to END as we know it?The Oxford ClubBiden Nomination CANCELED?The Freeport SocietyThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding First Trust Nasdaq Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
